Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes.

Breccia M, Carmosino I, Biondo F, Mancini M, Russo E, Latagliata R, Alimena G.

Leuk Res. 2006 Feb;30(2):178-82. Epub 2005 Aug 15.

PMID:
16102825
2.

Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.

Navarro I, Ruiz MA, Cabello A, Collado R, Ferrer R, Hueso J, Martinez J, Miguel A, Orero MT, Pérez P, Nolasco A, Carbonell F.

Leuk Res. 2006 Aug;30(8):971-7. Epub 2006 Jan 19.

PMID:
16423393
3.

Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.

Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B, Giagounidis A, Aul C, Gattermann N, Haas R.

Haematologica. 2006 Dec;91(12):1596-604.

4.

The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey.

Demirkan F, Alacacioglu I, Piskin O, Ozsan HG, Akinci B, Ozcan AM, Yavuzsen T, Yuksel E, Undar B.

Leuk Lymphoma. 2007 Jul;48(7):1372-8.

PMID:
17613766
5.
6.

[Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].

Yu MH, Xu ZF, Li L, Nie L, Liu L, Zhang Y, Qin TJ, Hao YS, Xiao ZJ.

Zhonghua Xue Ye Xue Za Zhi. 2009 Jan;30(1):3-7. Chinese.

PMID:
19563026
7.
8.

Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.

Lorand-Metze I, Pinheiro MP, Ribeiro E, de Paula EV, Metze K.

Leuk Res. 2004 Jun;28(6):587-94.

PMID:
15120935
9.

Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.

van de Loosdrecht AA, Westers TM, Westra AH, Dräger AM, van der Velden VH, Ossenkoppele GJ.

Blood. 2008 Feb 1;111(3):1067-77. Epub 2007 Oct 30.

10.

Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.

Rosati S, Mick R, Xu F, Stonys E, Le Beau MM, Larson R, Vardiman JW.

Leukemia. 1996 Jan;10(1):20-6.

PMID:
8558932
11.

Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients.

Breccia M, Latagliata R, Cannella L, Carmosino I, Santopietro M, Loglisci G, Federico V, Alimena G.

Leuk Lymphoma. 2010 May;51(5):783-8. doi: 10.3109/10428191003682759.

PMID:
20302387
12.

[Myelodisplasic syndromes diagnosed in a geriatric hospital: morphological profile in 100 patients].

Dewulf G, Gouin I, Pautas E, Gaussem P, Chaïbi P, Andreux JP, Siguret V.

Ann Biol Clin (Paris). 2004 Mar-Apr;62(2):197-202. French.

13.

Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution.

Nösslinger T, Reisner R, Koller E, Grüner H, Tüchler H, Nowotny H, Pittermann E, Pfeilstöcker M.

Blood. 2001 Nov 15;98(10):2935-41.

14.

[Karyotypic and IPSS grouping of primary myelodysplastic syndromes patients: a comparison between FAB- and WHO-classification].

Yu MH, Liu SH, Shao YQ, Hao YS, Xiao ZJ.

Zhonghua Xue Ye Xue Za Zhi. 2004 Aug;25(8):482-5. Chinese.

PMID:
15555265
15.

Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia.

Wang H, Wang XQ, Xu XP, Lin GW.

Eur J Haematol. 2009 Dec 1;83(6):550-8. doi: 10.1111/j.1600-0609.2009.01343.x. Epub 2009 Sep 8.

PMID:
19737310
16.

Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study.

Wang H, Wang X, Xu X, Lin G.

Ann Hematol. 2010 Jun;89(6):535-44. doi: 10.1007/s00277-009-0861-0. Epub 2009 Nov 17.

PMID:
19921190
17.

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, Cazzola M.

J Clin Oncol. 2005 Oct 20;23(30):7594-603. Epub 2005 Sep 26.

PMID:
16186598
18.

Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes.

Mohamedali A, Gäken J, Twine NA, Ingram W, Westwood N, Lea NC, Hayden J, Donaldson N, Aul C, Gattermann N, Giagounidis A, Germing U, List AF, Mufti GJ.

Blood. 2007 Nov 1;110(9):3365-73. Epub 2007 Jul 18.

19.

A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals.

Cabello AI, Collado R, Ruiz MA, Martínez J, Navarro I, Ferrer R, Sosa AM, Carbonell F.

Leuk Res. 2005 Apr;29(4):365-70. Epub 2004 Dec 2.

PMID:
15725469
20.

Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.

Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.

Transfusion. 2010 Jan;50(1):190-9. doi: 10.1111/j.1537-2995.2009.02361.x. Epub 2009 Aug 28.

PMID:
19719471

Supplemental Content

Support Center